Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma

AIDS

Volumn 27, Issue 6, 2013, Pages 1033-1035

  Corona, Giuseppe ^a   Vaccher, Emanuela ^b   Spina, Michele ^b   Toffoli, Giuseppe ^a  

^a Experimental and Clinical Pharmacology   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; BLEOMYCIN; CYTOCHROME P450 3A4; DACARBAZINE; DARUNAVIR PLUS RITONAVIR; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEINASE INHIBITOR; RITONAVIR; VINBLASTINE;

CANCER CHEMOTHERAPY; CASE REPORT; DRUG BLOOD LEVEL; DRUG EXPOSURE; ENZYME ACTIVITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIFE EXPECTANCY; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TREATMENT RESPONSE;

ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; DRUG ANTAGONISM; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HODGKIN DISEASE; HUMANS; TREATMENT OUTCOME; VINBLASTINE;

EID: 84876349410     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835e0777     Document Type: Letter

References (13)

1. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95.
2. May MT, Ingle SM. Life expectancy of HIV-positive adults: A review. Sex Health 2011; 8:526-533.
3. Deeken JF, Tjen AL, Rudek MA, Okuliar C, Young M, Little RF, et al. The Rising Challenge of Non-AIDS-Defining Cancers in HIV-Infected Patients. Clin Infect Dis 2012; 55:1228-1235.
4. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011; 103:753-762.
5. Cheung MC, Hicks LK, Leitch HA. Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010; 10:E22-E25.
6. Kotb R, Vincent I, Dulioust A, Peretti D, Taburet AM, Delfraissy JF, et al. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease. Eur J Haematol 2006; 76:269-271.
7. Makinson A, Martelli N, Peyriere H, Turriere C, Le MV, Reynes J. Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIVassociated Hodgkin's disease. Eur J Haematol 2007; 78:358- 360.
8. Spina M, Gabarre J, Rossi G, Fasan M, Schiantarelli C, Nigra E, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002; 100:1984-1988.
9. Xu L, Desai MC. Pharmacokinetic enhancers for HIV drugs. Curr Opin Investig Drugs 2009; 10:775-786.
10. Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Muller M, et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol 2012; 30:4117-4123.
11. Kaplan LD. Management of HIV-associated hodgkin lymphoma: how far we have come. J Clin Oncol 2012; 30:4056- 4058.
12. Hentrich M, Maretta L, Chow KU, Bogner JR, Schurmann D, Neuhoff P, et al. Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol 2006; 17:914-919.
13. Corona G, Casetta B, Sandron S, Vaccher E, Toffoli G. Rapid and sensitive analysis of vincristine in human plasma using on-line extraction combined with liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2008; 22:519- 525.